Donald Bergstrom Sells 18,895 Shares of Relay Therapeutics (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) insider Donald Bergstrom sold 18,895 shares of the stock in a transaction on Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total transaction of $143,979.90. Following the completion of the transaction, the insider directly owned 422,733 shares in the company, valued at $3,221,225.46. The trade was a 4.28% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Relay Therapeutics Stock Performance

NASDAQ RLAY opened at $7.66 on Friday. Relay Therapeutics, Inc. has a 52-week low of $1.77 and a 52-week high of $9.04. The company has a fifty day moving average of $7.97 and a 200-day moving average of $5.97. The company has a market capitalization of $1.33 billion, a P/E ratio of -4.38 and a beta of 1.55.

Relay Therapeutics (NASDAQ:RLAY) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). As a group, analysts forecast that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Institutional Trading of Relay Therapeutics

Several large investors have recently modified their holdings of the business. AQR Capital Management LLC lifted its holdings in Relay Therapeutics by 11.9% in the 1st quarter. AQR Capital Management LLC now owns 364,946 shares of the company’s stock worth $956,000 after buying an additional 38,812 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Relay Therapeutics by 6.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 84,069 shares of the company’s stock worth $221,000 after acquiring an additional 5,238 shares during the period. Millennium Management LLC boosted its holdings in Relay Therapeutics by 14.6% in the first quarter. Millennium Management LLC now owns 2,942,875 shares of the company’s stock valued at $7,710,000 after acquiring an additional 374,491 shares in the last quarter. Dynamic Technology Lab Private Ltd purchased a new position in Relay Therapeutics during the 1st quarter valued at $53,000. Finally, Woodline Partners LP raised its holdings in Relay Therapeutics by 448.4% in the 1st quarter. Woodline Partners LP now owns 1,518,561 shares of the company’s stock worth $3,979,000 after purchasing an additional 1,241,657 shares in the last quarter. 96.98% of the stock is owned by institutional investors.

Relay Therapeutics News Roundup

Here are the key news stories impacting Relay Therapeutics this week:

• Positive Sentiment: Technical/quote signal — MarketBeat notes an intraday uptick and that shares are trading above the 200‑day moving average, a constructive technical sign that can attract momentum buyers. MarketBeat RLAY quote
• Positive Sentiment: Analyst support — Recent upgrades (Oppenheimer to Outperform; Wells Fargo to Overweight) and a consensus “Moderate Buy” rating give fundamental/flow support that can limit downside from short‑term selling. Analyst commentary
• Neutral Sentiment: Insiders still hold large stakes — filings show executives retain hundreds of thousands of shares after the sales, so these transactions reduce ownership modestly but are not a change of control signal. (See SEC filings for details.) SEC ownership filing
• Negative Sentiment: CFO selling — CFO Thomas Catinazzo sold 13,820 shares on Jan. 27 (~$105k at ~$7.62) and an additional 1,695 shares on Jan. 28 (~$14.3k at ~$8.45). Multi‑day sales by the CFO amplify concerns and can sap near‑term sentiment. Catinazzo filings
• Negative Sentiment: Other insider sales clustered over Jan. 27–28 — Director/executive Peter Rahmer sold ~11.7k and 1,354 shares across two days; Donald Bergstrom sold ~18.9k and 2,686 shares. The concentration and timing of sales by multiple insiders increase short‑term selling pressure. Rahmer filings Bergstrom filings
• Negative Sentiment: Market commentary citing a notable intraday decline (~5.2%) amplifies negative sentiment and may trigger momentum selling even if fundamentals are unchanged. Why RLAY is down 5.18%

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on RLAY shares. Wells Fargo & Company upgraded shares of Relay Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the stock from $6.00 to $13.00 in a report on Friday, December 12th. Weiss Ratings reissued a “sell (d-)” rating on shares of Relay Therapeutics in a research note on Friday, January 9th. Finally, Oppenheimer upgraded shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price target for the company in a research report on Monday. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $16.57.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.